As of September 30, 2026, Cytek Biosciences, Inc. carries a market capitalization of 680.01M, placing it among publicly traded companies globally. Its enterprise value stands at 476.01M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 680.01M |
| Enterprise Value | 476.01M |
Cytek Biosciences, Inc.'s next confirmed earnings release is scheduled for March 4, 2027.
| Earnings Date | 3/4/2027 |
As of September 30, 2026, Cytek Biosciences, Inc. has 130.77M shares outstanding.
| Shares Outstanding | 130.77M |
These figures are as of September 30, 2026. The price-to-sales ratio is 3.67, and the price-to-book ratio stands at 2.40.
| PS Ratio | 3.67 |
| PB Ratio | 2.40 |
| P/TBV Ratio | 2.65 |
| P/FCF Ratio | -55.90 |
| P/OCF Ratio | -115.51 |
These figures are as of September 30, 2026. The EV/Sales ratio of 2.60 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 476.01M versus a market cap of 680.01M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 2.60 |
As of September 30, 2026, Cytek Biosciences, Inc. maintains a current ratio of 4.46, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.68, indicating elevated leverage, while an interest coverage ratio of -409.35 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.46 |
| Quick Ratio | 3.73 |
| Debt / Equity | 7.68 |
| Debt / EBITDA | -0.77 |
| Interest Coverage | -409.35 |
Over the twelve months ended September 30, 2026, Cytek Biosciences, Inc. posted a negative return on equity (ROE) of -23.20, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -17.26, reflecting losses generated across the asset base. The company generates approximately 261,721.69 in revenue per employee across its workforce of 700.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.81 indicates how many times Cytek Biosciences, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | -23.20 |
| Return on Assets (ROA) | -17.26 |
| Revenue Per Employee | 261,721.69 |
| Employee Count | 700.00 |
| Inventory Turnover | 1.81 |
Over the twelve months ended September 30, 2026, Cytek Biosciences, Inc. recorded 36.39M in income tax expense. The company reported a pretax loss of -35.25M and -71.64M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 36.39M |
As of the close on November 17, 2026, Cytek Biosciences, Inc.'s stock has gained approximately 11.84% over the past 52 weeks. The 50-day moving average sits at 4.91, while the 200-day moving average is 4.06.
| 52-Week Price Change | 11.84% |
| 50-Day Moving Average | 4.91 |
| 200-Day Moving Average | 4.06 |
Over the twelve months ended September 30, 2026, Cytek Biosciences, Inc. generated 183.21M in revenue and converted that into -71.64M in net income, yielding earnings per share of -0.55. EBITDA reached -28.17M, while operating income came in at -38.72M.
| Revenue | 183.21M |
| Gross Profit | 100.30M |
| Operating Income | -38.72M |
| Pretax Income | -35.25M |
| Net Income | -71.64M |
| EBITDA | -28.17M |
| EBIT | -38.72M |
| Earnings Per Share (EPS) | -0.55 |
As of September 30, 2026, Cytek Biosciences, Inc. holds 225.78M in cash and equivalents against 21.78M in total debt, resulting in a net debt position of -51.49M. Total book value stands at 283.53M, with working capital of 259.38M providing operational flexibility.
| Cash & Cash Equivalents | 225.78M |
| Total Debt | 21.78M |
| Net Debt | -51.49M |
| Equity (Book Value) | 283.53M |
| Book Value Per Share | 2.17 |
| Working Capital | 259.38M |
Cytek Biosciences, Inc. produced -5.82M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -6.20M in capital expenditures, free cash flow totaled -12.02M - equivalent to -0.09 per share.
| Operating Cash Flow | -5.82M |
| Capital Expenditures | -6.20M |
| Free Cash Flow | -12.02M |
| FCF Per Share | -0.09 |
Over the twelve months ended September 30, 2026, Cytek Biosciences, Inc. posted a gross margin of 54.75, reflecting its pricing power and cost economics. The operating margin of -21.13 and net profit margin of -39.10 provide insight into operational efficiency.
| Gross Margin | 54.75 |
| Operating Margin | -21.13 |
| Pretax Margin | -19.24 |
| Profit Margin | -39.10 |
| EBITDA Margin | -15.38 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -1.79: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.18, meaning Cytek Biosciences, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -0.18 |
| FCF Yield | -1.79 |
As of September 30, 2026, Cytek Biosciences, Inc. has an Altman Z-Score of 4.24, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.24 |